Vor Biopharma (VOR) Income from Continuing Operations (2020 - 2026)
Vor Biopharma (VOR) reported Income from Continuing Operations of 31225000.0 for Q1 2026, up 3.88% year-over-year from 30058237.77 in Q1 2025, and up 5.85% quarter-over-quarter from 33165000.0 in Q4 2025.
Vor Biopharma (VOR) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has 7 years of Income from Continuing Operations data on file, last reported at 31225000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 31225000.0, up 3.88% year-over-year; the trailing twelve-month figure through Mar 2026 was 364513000.0 (down 207.36% YoY), and the FY2025 annual result was 365774000.0, down 212.86% from the prior year.
- Income from Continuing Operations advanced to 31225000.0 in Q1 2026 per VOR's latest filing, from 33165000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 21659000.0 in Q2 2022 and troughed at 273747000.0 in Q2 2025.
- A 5-year average of 42580588.24 and a median of 28433000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations increased 16.97% in 2024, then sank 883.32% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 23910000.0 in 2022, then fell by 9.83% to 26261000.0 in 2023, then decreased by 16.95% to 30712000.0 in 2024, then fell by 7.99% to 33165000.0 in 2025, then advanced by 5.85% to 31225000.0 in 2026.
- Business Quant data shows VOR's Income from Continuing Operations at 31225000.0 in Q1 2026, 33165000.0 in Q4 2025, and 26376000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Vor Biopharma | 627.54 Mn | 627.54 Mn | - | -31.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.23 Mn |
| Dec 31, 2025 | -33.17 Mn |
| Sep 30, 2025 | -26.38 Mn |
| Jun 30, 2025 | -273.75 Mn |
| Mar 31, 2025 | -32.49 Mn |
| Dec 31, 2024 | -30.71 Mn |
| Sep 30, 2024 | -27.56 Mn |
| Jun 30, 2024 | -27.84 Mn |
| Mar 31, 2024 | -30.80 Mn |
| Dec 31, 2023 | -26.26 Mn |
| Sep 30, 2023 | -33.19 Mn |
| Jun 30, 2023 | -29.98 Mn |
| Mar 31, 2023 | -28.43 Mn |
| Dec 31, 2022 | -23.91 Mn |
| Sep 30, 2022 | -23.79 Mn |
| Jun 30, 2022 | -21.66 Mn |
| Mar 31, 2022 | -22.74 Mn |
| Dec 31, 2021 | -18.25 Mn |
| Sep 30, 2021 | -18.55 Mn |
| Jun 30, 2021 | -18.37 Mn |